This is a working overview of visceral fat, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-18. Anything still debated is marked as such rather than presented as settled.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Tyrannosaurus, like most dinosaurs, was long thought to have an ectothermic ("cold-blooded") reptilian metabolism. The idea of dinosaur ectothermy was challenged by scientists like Robert T. Bakker and John Ostrom in the early years of the "dinosaur renaissance", beginning in the late 1960s. T. rex itself was claimed to have been endothermic ("warm-blooded"), implying a very active lifestyle. Since then, several paleontologists have sought to determine the ability of Tyrannosaurus to regulate its body temperature. Histological evidence of high growth rates in young T. rex, comparable to those of mammals and birds, may support the hypothesis of a high metabolism. Growth curves indicate that, as in mammals and birds, T. rex growth was limited mostly to immature animals, rather than the indeterminate growth seen in most other vertebrates. Oxygen isotope ratios in fossilized bone are sometimes used to determine the temperature at which the bone was deposited, as the ratio between certain isotopes correlates with temperature. In one specimen, the isotope ratios in bones from different parts of the body indicated a temperature difference of no more than 4 to 5 °C (7 to 9 °F) between the vertebrae of the torso and the tibia of the lower leg. This small temperature range between the body core and the extremities was claimed by paleontologist Reese Barrick and geochemist William Showers to indicate that T. rex maintained a constant internal body temperature (homeothermy) and that it enjoyed a metabolism somewhere between ectothermic reptiles and endothermic mammals.
=== Acute bone fracture care === Bone fractures are treated in individuals with osteogenesis imperfecta in much the same way as they are treated in the general population; OI bone heals at the same rate as non-OI bone. A greater emphasis is placed on using lightweight materials to immobilize the fracture, as in moderate or severe types of OI, using heavy casts, such as hip spica casts, can cause fractures at the bones at the boundaries of the cast, as well as generalized osteopenia. The lightweight cast or splint is then replaced with a removable orthosis after a few weeks and once evidence of union is seen on X-ray. To prevent a nonunion or malunion, all fractures should be immobilized, even if the fracture seems trivial (microfracture), as people with OI are at greater risk of nonunion. Bone infections secondary to fractures are treated as and when they occur with the appropriate antibiotics and antiseptics, as in the general population.
Fibrils (from Latin fibra) are structural biological materials found in nearly all living organisms. Not to be confused with fibers or filaments, fibrils tend to have diameters ranging from 10 to 100 nanometers (whereas fibers are micro to milli-scale structures and filaments have diameters approximately 10–50 nanometers in size). Fibrils are not usually found alone but rather are parts of greater hierarchical structures commonly found in biological systems. Due to the prevalence of fibrils in biological systems, their study is of great importance in the fields of microbiology, biomechanics, and materials science.
In the brain, hyaluronan serves as the primary component of the extracellular matrix, contributing to both structural integrity and signaling functions. High-molecular-weight hyaluronan forms a diffusional barrier that regulates local extracellular diffusion. When the ECM undergoes degradation, hyaluronan fragments are released into the extracellular space, where they act as pro-inflammatory molecules, influencing immune cell responses, including those of microglia.
Sources: en.wikipedia.org
=== Contraindications === Both rosiglitazone and pioglitazone are contraindicated in people with NYHA Class III and IV heart failure. They are not recommended for use in heart failure. In Europe, rosiglitazone was contraindicated for heart failure or history of heart failure with regard to all NYHA stages, for combined use with insulin and for acute coronary syndrome. The European Medicines Agency recommended on 23 September 2010 that Avandia be suspended from the European market.
The KSC stated that Thaçi played a key role in "formulating and implementing the common purpose" of the crimes, and that he "personally participated in crimes, including the arrest, arbitrary detention and interrogation of 13 parliamentarians and the arrest, detention, transfer and murder of Behajdin Allaqi." The KSC found that Thaçi had made false statements about victims and detainees and gave "false assurances of compliance with international humanitarian law on behalf of the KLA."
== Notable ascents == 1953 2nd ascent Yosemite Point Buttress. (With Royal Robbins) 1953 2nd ascent North Face Sentinel Rock. (With Royal Robbins and Don Wilson) 1953 Palisades Traverse Thunderbolt Peak to Mount Sill via North Palisade. (With Gary Hemming) 1954 5th ascent Lost Arrow Spire. (With Wayne Merry) 1955 3rd ascent Lost Arrow Chimney. (With Charles Wilts and Don Wilson) 1956 1st ascent Spider Rock, Canyon de Chelly National Monument, AZ, USA, March 30. (With Mark Powell and Don Wilson) 1956 1st ascent East Buttress of Middle Cathedral Rock, Yosemite National Park, CA, USA, June 16. (With Mark Powell and Don Wilson) 1956 5th ascent Castle Rock Spire. (With Charles Wilts) 1956 1st ascent Cleopatra's Needle, Valley of the Thundering Water, NM, USA, September 6. (With Mark Powell and Don Wilson) 1957 1st ascent The Step, Tahquitz Idyllwild, CA, USA, May 18. (With Royal Robbins) 1957 1st ascent Totem Pole, Monument Valley, AZ, USA. June 13. (With Bill Feuerer, Mark Powell, and Don Wilson) 1957 1st ascent Northwest Face of Half Dome, Yosemite, CA, USA, June 23–27. First grade VI climb in America. (With Mike Sherrick and Royal Robbins)
== Research and innovation == BioDuro is involved in developing data-driven and automated workflows intended to accelerate discovery timelines. The company has partnered with technology firms, including Atombeat, to integrate AI-supported peptide-design platforms with high-throughput peptide synthesis and iterative screening workflows. According to the company, these approaches are designed to reduce design–test cycles in peptide and bioconjugate programs; independent evaluation of the platform’s performance is still limited in publicly available literature.
The following year he was elected to membership at the Institute of Medicine. In 1987, he became Professor Emeritus of Medicine at Harvard Medical School. One year later he was the first Paul Klemperer Award recipient at the New York Academy of Medicine. In 1995, Gross won the Lifetime Achievement Award of The Wound Healing Society.
Sources: en.wikipedia.org
Although towards the end of the century, MacBride's theories were being challenged, the medical authorities in Britain remained committed to the notion that scurvy was a disease of internal 'putrefaction' and the Sick and Hurt Board, run by administrators, felt obliged to follow its advice. Within the Royal Navy, however, opinion – strengthened by first-hand experience with lemon juice at the siege of Gibraltar and during Admiral Rodney's expedition to the Caribbean – had become increasingly convinced of its efficacy. This was reinforced by the writings of experts like Gilbert Blane and Thomas Trotter and by the reports of up-and-coming naval commanders. With the coming of war in 1793, the need to eliminate scurvy became more urgent. The first initiative came not from the medical establishment but from the admirals. Ordered to lead an expedition against Mauritius, Rear Admiral Gardner was uninterested in the wort, malt, and elixir of vitriol that were still being issued to ships of the Royal Navy, and demanded that he be supplied with lemons, to counteract scurvy on the voyage. Members of the Sick and Hurt Board, recently augmented by two practical naval surgeons, supported the request, and the Admiralty ordered that it be done. There was, however, a last-minute change of plan, and the expedition against Mauritius was canceled. On 2 May 1794, only HMS Suffolk and two sloops under Commodore Peter Rainier sailed for the east with an outward bound convoy, but the warships were fully supplied with lemon juice and the sugar with which it had to be mixed.
==== Autonomic problems ==== Although neurogastroenterological manifestations in connective tissue disorders are common, their root cause is not yet known. Splanchnic circulation, small fiber neuropathy and altered vascular compliance have all been named as potential contributors to gastrointestinal complaints, particularly for patients who have a known, comorbid autonomic condition. Dysautonomia symptoms, autonomic system dysfunction, in hEDS is associated with exercise intolerance and cardiac atrophy.
=== Atomic and physical === Flerovium is in group 14 in the periodic table, below carbon, silicon, germanium, tin, and lead. Every previous group 14 element has 4 electrons in its valence shell, hence valence electron configuration ns2np2. For flerovium, the trend will continue and the valence electron configuration is predicted as 7s27p2; flerovium will be similar to its lighter congeners in many ways. Differences are likely to arise; a large contributor is spin–orbit (SO) interaction—mutual interaction between the electrons' motion and spin. It is especially strong in superheavy elements, because the electrons move faster than in lighter atoms, at speeds comparable to the speed of light. For flerovium, it lowers the 7s and the 7p electron energy levels (stabilizing the corresponding electrons), but two of the 7p electron energy levels are stabilized more than the other four. The stabilization of the 7s electrons is called the inert pair effect, and the effect "tearing" the 7p subshell into the more and less stabilized parts is called subshell splitting. Computational chemists see the split as a change of the second (azimuthal) quantum number ℓ from 1 to 1⁄2 and 3⁄2 for the more stabilized and less stabilized parts of the 7p subshell, respectively. For many theoretical purposes, the valence electron configuration may be represented to reflect the 7p subshell split as 7s27p21/2. These effects cause flerovium's chemistry to be somewhat different from that of its lighter neighbours.
A memorandum to end the war was signed on 17 June by the presidents of the US and Iran, lifting the dual blockade. Tensions again escalated, but on 28 June, the US and Iran agreed to cease their exchange of attacks. On 8 July, the ceasefire deal between the US and Iran collapsed after Iran initiated attacks on commercial vessels in the Strait of Hormuz to assert sovereignty over the strait, which interrupted a brief diplomatic lull.
Evidence from the study of extant Japanese macaques, indicating that the initial shift from quadrupedalism to bipedalism in the hominin evolution might have involved a shift of the primary action of the gluteus medius without any required morphological change, is presented by Shitara et al. (2026). Sekhavati, Prang & Strait (2026) study the relationships between hominin foot morphology and environmental context throughout the evolutionary history of hominins, and link the emergence of hominin bipedalism to increases of aridity in Central and Eastern Africa. Carlson et al. (2026) determine relative limb strength in Australopithecus and early members of the genus Homo, interpreted as indicative of frequent arboreal behavior in Australopithecus, as well as indicative of departure of hominins from arboreality by ∼1.8 million years ago. Kurki & Wall-Scheffler (2026) study the variation of pelvic canal dimensions in extant humans and extinct hominins, finding no evidence of a single trajectory of evolution of hominin pelvic shape. Komza, Viola & Schroeder (2026) interpret the evolution of the morphology of hominin midfoot as affected by selection for bipedalism in the lateral side in early bipeds such as Ardipithecus ramidus and shaped by a broad range of evolutionary processes in later hominins.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.